0.07
+0.0035(+5.05%)
Currency In USD
| Previous Close | 0.07 |
| Open | 0.08 |
| Day High | 0.08 |
| Day Low | 0.07 |
| 52-Week High | 21.4 |
| 52-Week Low | 0.05 |
| Volume | 4.24M |
| Average Volume | 8.82M |
| Market Cap | 3.23M |
| PE | 0 |
| EPS | -87.25 |
| Moving Average 50 Days | 0.12 |
| Moving Average 200 Days | 2.25 |
| Change | 0 |
If you invested $1000 in Onconetix, Inc. (ONCO) since IPO date, it would be worth $0.03 as of May 09, 2025 at a share price of $0.073. Whereas If you bought $1000 worth of Onconetix, Inc. (ONCO) shares 2 years ago, it would be worth $1.78 as of May 09, 2025 at a share price of $0.073.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
GlobeNewswire Inc.
Apr 30, 2025 10:13 PM GMT
Cincinnati, OH, April 30, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on April 24, 2025 indicating that the Company’s failure
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
GlobeNewswire Inc.
Apr 08, 2025 12:30 PM GMT
CINCINNATI, April 08, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) (formerly Blue Water Biotech Inc.) and Ocuvex Therapeutics, Inc. (“Ocuvex”), a privately held biopharmaceutical company focused on the dev
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
GlobeNewswire Inc.
Mar 24, 2025 12:45 PM GMT
CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of in